SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Drug Development
NEJM Publishes Data Touting Efficacy of TG Therapeutics’ MS Drug
August 26, 2022
 · 
3 min read
 · 
Alex Keown
Drug Development
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
August 25, 2022
 · 
11 min read
Business
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsConference call to be held today, August 8, 2022 at 8:30 AM ET
August 8, 2022
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Second Quarter 2022 Financial Results and Business UpdateConference call to be held Monday, August 8, 2022 at 8:30 AM ET
August 5, 2022
 · 
1 min read
Drug Development
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
June 27, 2022
 · 
7 min read
Sarah Silbiger/Getty Images
Drug Development
FDA Action Alert: BMS, TG, Spero and Merck
June 17, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
June 3, 2022
 · 
7 min read
Pictured: Stop sign in front of FDA headquarters/S
FDA
FDA Pulls Approval for TG Therapeutics’ Cancer Drug
June 1, 2022
 · 
3 min read
 · 
Alex Keown
Sarah Silbiger/Getty Images
Drug Development
TG Will Have to Wait Till December for MS Drug Decision Date
May 31, 2022
 · 
2 min read
 · 
Jazmine Colatriano, M.S.
Pharm Country
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMSNew PDUFA goal date of December 28, 2022
May 31, 2022
 · 
7 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
May 26, 2022
 · 
8 min read
Pharm Country
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET
May 20, 2022
 · 
1 min read
Pharm Country
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022
 · 
1 min read
Policy
FDA Committee Shuts Door on Single-Arm Trials for PI3K Inhibitors
April 21, 2022
 · 
4 min read
 · 
Alex Keown
Jason Armond / Los Angeles Times via Getty Images
Drug Development
FDA’s Cancer Advisory Committee to Evaluate Safety of PI3K inhibitors
April 20, 2022
 · 
5 min read
 · 
Mark Terry
Pictured: Stop sign in front of FDA headquarters/S
Drug Development
TG Therapeutics Backpedals on BLA for Lymphoma, Leukemia Treatment
April 15, 2022
 · 
3 min read
 · 
Mark Terry
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS